Collagen Type I and Type III (COL1/COL3)

Collagen Type I and Type III are the primary fibrillar collagens that constitute the majority of the interstitial extracellular matrix in vertebrates, providing essential structural integrity and tensile strength to tissues such as skin, bone, tendons, and internal organs (UniProt P02452, P02461). Type I collagen is the most abundant protein in the human body, forming thick fibers, whereas Type III collagen forms thinner reticular fibers and is particularly prominent in distensible organs and during the initial phases of wound healing (PubMed: 26319235). Pathologically, the overproduction and cross-linking of these collagens are central to the development of fibrosis in the liver, lungs, and kidneys, leading to organ failure (StatPearls: Collagen Structure). Conversely, genetic mutations or age-related degradation of these proteins result in conditions like Osteogenesis imperfecta, Ehlers-Danlos syndrome, and skin atrophy (NIH: Genetics Home Reference). Therapeutic approaches include the use of collagenase enzymes to break down excessive deposits in conditions like Dupuytren's contracture, as well as the use of retinoids and dermal fillers to stimulate collagen synthesis for aesthetic and regenerative purposes (PubChem: Collagenase clostridium histolyticum).

Other names

Fibrillar collagenType I collagenType III collagenCOL1A1COL1A2COL3A1Alpha-1 type I collagenAlpha-1 type III collagen

Drugs targeting Collagen Type I and III act through several mechanisms: enzymatic degradation of existing collagen fibers (e.g., collagenase), stimulation of de novo collagen synthesis by fibroblasts (e.g., dermal fillers and retinoids), or inhibition of signaling pathways like TGF-beta that lead to excessive collagen deposition in fibrotic diseases (e.g., anti-fibrotics).